Pharming Group N.V.

NASDAQ:PHAR

Biotechnology

Healthcare
$12.48 +2.19%

+$0.28 today

Market cap
$882.43M
Beta
0.10
P/E (TTM)
77.0
EPS (TTM)
$0.02
52W Low $9.54High $21.34

Volume 0.01M

Average 0.01M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

$50.07M

FY 2025 · Annual

Investing Cash Flow

$18.43M

FY 2025 · Annual

-43.7% YoY

Financing Cash Flow

$14.48M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income26.16M14.99M(12.01M)(8.79M)2.86M
Depreciation & Amortization22.23M13.19M15.93M16.64M0
Deferred Income Tax00000
Stock-Based Compensation10.27M6.39M9.25M11.65M0
Change in Working Capital(5.62M)(387K)(16.96M)(10.43M)14.4M
Accounts Receivables6.71M2.36M(18.54M)(7.02M)(3.36M)
Inventory(6.98M)(15.02M)(14.43M)(520.85K)(1.29M)
Accounts Payables000017.87M
Other Working Capital(5.36M)12.27M16.01M(2.88M)1.19M
Other Non-Cash Items(10.14M)(11.72M)(13.51M)(10.92M)32.8M
Operating Cash Flow42.9M22.46M(17.3M)(1.86M)50.07M
Capital Expenditures(18.95M)(1.98M)(1.46M)(824.25K)(751.09K)
Acquisitions (Net)07.3M00(65.53M)
Purchases of Investments(5.2M)0(382.01M)(294.4M)0
Sales of Investments00232.81M327.97M0
Other Investing Activities0021.28M084.72M
Investing Cash Flow(24.15M)5.32M(129.39M)32.74M18.43M
Debt Repayment(3.65M)(3.31M)(4.04M)(35.61M)0
Common Stock Issued5.35M2.28M0019.87M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(33.39M)(3.95M)3M(19.67K)(5.39M)
Financing Cash Flow(31.68M)(4.98M)(1.04M)(35.63M)14.48M
Effect of Forex Changes(2.07M)(7.38M)2.13M(2.29M)8.12M
Net Change in Cash(15M)15.42M(145.6M)(7.04M)91.09M
Free Cash Flow23.95M20.48M(18.77M)(2.68M)49.31M

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income$2.9M
+ D&A$0
+ Stock-Based Comp$0
+ Deferred Tax$0
+ Working Capital$14.4M
+ Other Non-Cash$32.8M
= Operating Cash Flow$50.1M
- Capex-$751.1K
= Free Cash Flow$49.3M

Analysis

FY2025 free cash flow is $49.3M. FCF conversion is 1724.9% of net income. Operating cash flow was $50.1M, with capex of -$751.1K. The largest bridge item is Other Non-Cash at $32.8M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
6-K6-K filingNov 6, 2026
6-K6-K filingOct 27, 2026
6-K6-K filingOct 22, 2026
6-K6-K filingOct 14, 2026
6-K6-K filingSep 29, 2026

Does PHAR generate free cash flow?

Pharming Group N.V. (PHAR) generated $49.31M of free cash flow in fiscal 2025.

How much operating cash flow does PHAR produce?

Operating cash flow was $50.07M, before capital expenditures of $751,090.00.